University Hospital of Basel

MindMed Reports 2023 Financial Results and Business Updates

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Senior, Week, ODT, MindMed, FDA, University Hospital of Basel, DSM-IV codes, Standard of care, GAD, Patient, Anxiety, Medicine, Pharmaceutical industry

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada:MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the year ended December 31, 2023 and provided a business update.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada:MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the year ended December 31, 2023 and provided a business update.
  • “2023 was a highly productive year for MindMed, which concluded with positive Phase 2b results for MM120 in the treatment of adult patients with GAD,” said Rob Barrow, Chief Executive Officer and Director of the Company.
  • As of December 31, 2023, MindMed had cash and cash equivalents totaling $99.7 million compared to $142.1 million as of December 31, 2022.
  • MindMed management will host a conference call at 8:00 AM EST today to provide a corporate update and review the Company’s 2023 financial results.

Personalized Health Basel and Leading Life Sciences Organization Collaborate with MDClone to Drive Innovation

Retrieved on: 
Tuesday, February 13, 2024
Senior, USB, Patient, Clinical trial, Privacy, International business, Linearity, Research, University Hospital of Basel, Partnership, Nursing

BEER-SHEVA, Israel, Feb. 13, 2024 /PRNewswire/ -- MDClone, a leading data analytics and synthetic data company, announced today that it has established a partnership with the University Hospital Basel and a leading life sciences organization to build an infrastructure that will evolve how life sciences and pharma research is performed in the region. 

Key Points: 
  • BEER-SHEVA, Israel, Feb. 13, 2024 /PRNewswire/ -- MDClone, a leading data analytics and synthetic data company, announced today that it has established a partnership with the University Hospital Basel and a leading life sciences organization to build an infrastructure that will evolve how life sciences and pharma research is performed in the region.
  • USB and its life science partner are implementing MDClone's ADAMS Platform, which enables researchers to analyze health outcomes from large multi-source data sets while maintaining key privacy requirements through synthetic data capabilities.
  • Synthetic data is artificially created information that replicates the characteristics and correlations of real patient populations without jeopardizing patient privacy.
  • "We're on a mission to expand our horizons globally and form meaningful partnerships with elite institutions like Personalized Health Basel," said Davidi Bachrach, Senior Vice President of International Business at MDClone.

How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

Retrieved on: 
Wednesday, January 24, 2024
Teaching hospital, Research, Anxiety, Life, Benzodiazepine, MADRS, MindMed, NEO, Diagnosis, Depression, Growth, Therapy, Disorder, Psilocybin, Hackensack Meridian Health, Safety, DSM-IV codes, Phase, PALM, GAD, Buspirone, Mental health, PD, University Hospital of Basel, Quality of life, Call-progress tone, CMPS, Patient, Generalized anxiety disorder, Food, HMH, FDA, EU4, Anticonvulsant, DMT, News, Pharmaceutical industry

PALM BEACH, Fla., Jan. 24, 2024 /PRNewswire/ -- The coming years could see a massive shift in the U.S. government's approach to regulating hallucinogenic drugs. Several biopharma companies are developing psychedelics-based treatments for various mental health conditions like Generalized Anxiety Disorder (GAD). GAD is a prevalent mental health condition characterized by excessive and persistent worry, often extending beyond specific triggers. Individuals with GAD experience heightened levels of anxiety, anticipating future events and exhibiting physical symptoms such as muscle tension and restlessness. The disorder significantly impairs daily functioning and quality of life. A report from Delveinsight said that the total market size of the Generalized Anxiety Disorder (GAD) treatment market is anticipated to experience growth during the forecast period (2032) due to the emergence of new and effective treatments, especially numerous trials developing new and innovative next-generation psychedelic treatment options. The report added: "The diagnosis of Generalized Anxiety Disorder (GAD) involves a comprehensive assessment of an individual's mental health, considering the presence of excessive and uncontrollable worry across various aspects of life for a minimum of six months. Clinicians utilize standardized psychiatric interviews and validated screening tools to evaluate the severity of anxiety symptoms, along with a thorough exploration of associated physical and psychological manifestations. Differential diagnosis is crucial to rule out other psychiatric conditions, medical disorders, or substance-related issues that may mimic GAD symptoms. The diagnostic process also entails considering the impact of anxiety on daily functioning and its persistence in the absence of identifiable stressors. A multidimensional approach aids in ensuring an accurate diagnosis and facilitates the development of an effective treatment plan tailored to the individual's needs." Active Companies active today in markets include: Cybin Inc. (NYSE: CYBN) (NEO: CYBN), COMPASS Pathways plc (NASDAQ: CMPS), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), Seelos Therapeutics, Inc. (NASDAQ: SEEL), atai Life Sciences (NASDAQ: ATAI).

Key Points: 
  • Several biopharma companies are developing psychedelics-based treatments for various mental health conditions like Generalized Anxiety Disorder (GAD).
  • It continued: "DelveInsight's analyst projects that among the total diagnosed prevalent cases of Generalized Anxiety Disorder (GAD) in 7MM approximately 53% of cases were from the US.
  • The Generalized Anxiety Disorder (GAD) market is projected to witness consistent growth throughout the forecast period (2023–2032).
  • The market size of Generalized Anxiety Disorder (GAD) in the 7MM is expected to increase, driven by better diagnosis and the launch of emerging therapies."

How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

Retrieved on: 
Wednesday, January 24, 2024
Teaching hospital, Research, Anxiety, Life, Benzodiazepine, MADRS, MindMed, NEO, Diagnosis, Depression, Growth, Therapy, Disorder, Psilocybin, Hackensack Meridian Health, Safety, DSM-IV codes, Phase, PALM, GAD, Buspirone, Mental health, PD, University Hospital of Basel, Quality of life, Call-progress tone, CMPS, Patient, Generalized anxiety disorder, Food, HMH, FDA, EU4, Anticonvulsant, DMT, News, Pharmaceutical industry

PALM BEACH, Fla., Jan. 24, 2024 /PRNewswire/ -- The coming years could see a massive shift in the U.S. government's approach to regulating hallucinogenic drugs. Several biopharma companies are developing psychedelics-based treatments for various mental health conditions like Generalized Anxiety Disorder (GAD). GAD is a prevalent mental health condition characterized by excessive and persistent worry, often extending beyond specific triggers. Individuals with GAD experience heightened levels of anxiety, anticipating future events and exhibiting physical symptoms such as muscle tension and restlessness. The disorder significantly impairs daily functioning and quality of life. A report from Delveinsight said that the total market size of the Generalized Anxiety Disorder (GAD) treatment market is anticipated to experience growth during the forecast period (2032) due to the emergence of new and effective treatments, especially numerous trials developing new and innovative next-generation psychedelic treatment options. The report added: "The diagnosis of Generalized Anxiety Disorder (GAD) involves a comprehensive assessment of an individual's mental health, considering the presence of excessive and uncontrollable worry across various aspects of life for a minimum of six months. Clinicians utilize standardized psychiatric interviews and validated screening tools to evaluate the severity of anxiety symptoms, along with a thorough exploration of associated physical and psychological manifestations. Differential diagnosis is crucial to rule out other psychiatric conditions, medical disorders, or substance-related issues that may mimic GAD symptoms. The diagnostic process also entails considering the impact of anxiety on daily functioning and its persistence in the absence of identifiable stressors. A multidimensional approach aids in ensuring an accurate diagnosis and facilitates the development of an effective treatment plan tailored to the individual's needs." Active Companies active today in markets include: Cybin Inc. (NYSE: CYBN) (NEO: CYBN), COMPASS Pathways plc (NASDAQ: CMPS), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), Seelos Therapeutics, Inc. (NASDAQ: SEEL), atai Life Sciences (NASDAQ: ATAI).

Key Points: 
  • Several biopharma companies are developing psychedelics-based treatments for various mental health conditions like Generalized Anxiety Disorder (GAD).
  • It continued: "DelveInsight's analyst projects that among the total diagnosed prevalent cases of Generalized Anxiety Disorder (GAD) in 7MM approximately 53% of cases were from the US.
  • The Generalized Anxiety Disorder (GAD) market is projected to witness consistent growth throughout the forecast period (2023–2032).
  • The market size of Generalized Anxiety Disorder (GAD) in the 7MM is expected to increase, driven by better diagnosis and the launch of emerging therapies."

PulseAI's Groundbreaking AI Algorithm Enhances Consumer ECG Diagnostics

Retrieved on: 
Thursday, January 11, 2024
Classification, ECG, Patient, Research, Burden, Cardiology, Alivecor, Health, Intelligence, Atrial fibrillation, Stroke, AI, Algorithm, Samsung, University Hospital of Basel, Apple, Physician, Medical device

BELFAST, Northern Ireland, Jan. 11, 2024 /PRNewswire/ -- PulseAI, a leader in artificial intelligence healthcare solutions, today announced a significant advancement in consumer device electrocardiogram (ECG) monitoring. Published in the Cardiovascular Digital Health Journal, the new study titled "Reducing the Burden of Inconclusive Smart-Device Single-lead ECG Tracings via a Novel Artificial Intelligence Algorithm" showcases the impactful role of PulseAI's neural network algorithm in cardiac monitoring.

Key Points: 
  • Published in the Cardiovascular Digital Health Journal, the new study titled " Reducing the Burden of Inconclusive Smart-Device Single-lead ECG Tracings via a Novel Artificial Intelligence Algorithm " showcases the impactful role of PulseAI's neural network algorithm in cardiac monitoring.
  • The results demonstrate that PulseAI's neural network algorithm significantly reduces inconclusive diagnoses from commercially available consumer ECG devices by Apple, Samsung, AliveCor and Fitbit.
  • The research highlights the challenge of high rates of inconclusive readings from consumer ECG devices.
  • PulseAI's algorithm offers a reliable, cross-platform solution that integrates seamlessly with various consumer and clinical ECG devices.

PulseAI's Groundbreaking AI Algorithm Enhances Consumer ECG Diagnostics

Retrieved on: 
Thursday, January 11, 2024
Classification, ECG, Patient, Research, Burden, Cardiology, Alivecor, Health, Intelligence, Atrial fibrillation, Stroke, AI, Algorithm, Samsung, University Hospital of Basel, Apple, Physician, Medical device

BELFAST, Northern Ireland , Jan. 11, 2024 /PRNewswire/ -- PulseAI, a leader in artificial intelligence healthcare solutions, today announced a significant advancement in consumer device electrocardiogram (ECG) monitoring. Published in the Cardiovascular Digital Health Journal, the new study titled "Reducing the Burden of Inconclusive Smart-Device Single-lead ECG Tracings via a Novel Artificial Intelligence Algorithm" showcases the impactful role of PulseAI's neural network algorithm in cardiac monitoring.

Key Points: 
  • Published in the Cardiovascular Digital Health Journal, the new study titled " Reducing the Burden of Inconclusive Smart-Device Single-lead ECG Tracings via a Novel Artificial Intelligence Algorithm " showcases the impactful role of PulseAI's neural network algorithm in cardiac monitoring.
  • The results demonstrate that PulseAI's neural network algorithm significantly reduces inconclusive diagnoses from commercially available consumer ECG devices by Apple, Samsung, AliveCor and Fitbit.
  • The research highlights the challenge of high rates of inconclusive readings from consumer ECG devices.
  • PulseAI's algorithm offers a reliable, cross-platform solution that integrates seamlessly with various consumer and clinical ECG devices.

Implenia wins building construction contracts in Switzerland and Germany worth a total of over CHF 220 million

Retrieved on: 
Monday, December 25, 2023
Division, MBH, SIX Swiss Exchange, University Hospital of Basel, Restaurant, Terra, Sale, Tenant, HPE, CHF, 2000-watt society, Renta, Greater Poland Voivodeship, FTE, USB, Zurich Airport, Lean, Master Builder, Risk, Real estate, Corporate communication, Housing, Cryptocurrency, Commercial property, Construction, Property management, Opfikon, Oberwil, Implenia

Glattpark (Opfikon), 15 December 2023 – Implenia’s Division Buildings has won construction contracts in various regions of Switzerland and Germany worth a total of over CHF 220 million.

Key Points: 
  • Glattpark (Opfikon), 15 December 2023 – Implenia’s Division Buildings has won construction contracts in various regions of Switzerland and Germany worth a total of over CHF 220 million.
  • Implenia CEO André Wyss is delighted with the new orders: "These projects confirm the trust that our clients have in Implenia.
  • The project was supported by RECP throughout all the service phases, and was developed quickly thanks to Lean project structures.
  • The project, with an area of 24,700 m2, includes the construction of two rental apartment blocks and an office building.

University of Basel Delivers First Biological Implants for Treatment of Cartilage Lesions and Osteoarthritis in Humans

Retrieved on: 
Wednesday, November 15, 2023
Research, Surgery, FDA, Clinical Trials, Stem Cells, Other Health, Biotechnology, Physical Therapy, Health, Science, Spotify, N, Sport, Knee, Teaching hospital, Life, Ankle, Patient, Rheumatoid arthritis, Knee pain, Arthritis, Ice, Nasal septum, University Children's Hospital Basel, Torture, Doctor of Philosophy, Skiing, Quality of life, Government, Inflammation, Crutch, Swiss National Science Foundation, Surgeon, Tissue engineering, Cartilage, Regenerative medicine, European, University Hospital of Basel, Arthralgia, University of Basel, Chondrocyte, Animal, OA, University, Elbow, Apple, Walking, Cell, Motion, Brain, Hope, Joint, PFOA, MD, Human, Swimming, Leg, Dentistry, Pharmaceutical industry, Osteoarthritis

The Department of Biomedicine at the University of Basel and the University Hospital Basel, today announced that it delivered the first surgical procedure to treat Osteoarthritis (OA) in humans.

Key Points: 
  • The Department of Biomedicine at the University of Basel and the University Hospital Basel, today announced that it delivered the first surgical procedure to treat Osteoarthritis (OA) in humans.
  • Chondrocytes are the cell building blocks for cartilage and the University of Basel team is using them to grow new cartilage.
  • Expanding beyond focal lesions six years ago, the University of Basel team treated two patients with advanced knee OA – patients who had been scheduled for knee joint replacement.
  • The team at the University of Basel are providing folks like us with new hope.

ARTIDIS Launches Groundbreaking ANGEL Study With Over 2,700 Participants: Transforming Breast Cancer Diagnosis and Personalized Therapy Optimization at the Patient's Bedside

Retrieved on: 
Thursday, November 2, 2023
Trial of the century, MRI, NAT, Literature, Liver, Baylor University, Breast Cancer Awareness Month, University Hospital of Basel, Nanomechanics, Malignancy, Neoadjuvant therapy, Baylor College of Medicine, Mammography, Aggression, NANO, Breast cancer, Biopsy, Travel, Skin, Patient, Diagnosis, Medical imaging

The study aims to enroll over 2,700 patients, generating comprehensive insights into all breast cancer subtypes.

Key Points: 
  • The study aims to enroll over 2,700 patients, generating comprehensive insights into all breast cancer subtypes.
  • Dr. Alastair Thompson commented, “As a breast surgeon, I believe this study holds immense importance for breast cancer patients.
  • The ANGEL study specifically addresses the key challenges of personalized diagnosis and treatment decision-making, particularly in the field of neoadjuvant therapy.
  • Ensuring patients receive the best possible treatment from the start is crucial for improving outcomes for breast cancer patients.

MindMed Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Neurology, Other Health, Health, Clinical Trials, Week, Spectrum, AISRS, Congress, Prevalence, G&A, Telephone, Finance, University Hospital of Basel, Volunteering, Research, Pharmacokinetics, Growth, Attention deficit hyperactivity disorder predominantly inattentive, Clinical trial, Medicine, ECNP, Webcast, Research and development, Anticipation, European College of Neuropsychopharmacology, USD, GAD, NEO, UHB, ASD, MindMed, Patient, Administration, ADHD, Pharmaceutical industry, Birth control, Dietary supplement, Vaccine, Cryptocurrency, R

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the quarter ended September 30, 2023.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the quarter ended September 30, 2023.
  • Dosing is complete with topline results for the primary endpoint (Week 4) expected to be announced in Q4 2023.
  • R&D expenses were $13.2 million for the quarter ended September 30, 2023, compared to $7.8 million for the quarter ended September 30, 2022, an increase of $5.4 million.
  • MindMed management will host a conference call at 4:30 PM EST today to provide a corporate update and review the Company’s third quarter 2023 financial results.